Oscotec/ADEL Initiates First-in-Human Dosing in Ph1 of Anti-MTBR Tau Antibody ADEL-Y01 In Alzheimer's Disease
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study
IPOs spawn instant billionaires
More than half of Korean biopharma firms view R&D investments as assets.
Yuhan ups investment in biotechs for immuno-oncology drug push
Genosco gears up for IPO
Lazertinib Shows Promising Antitumor Activity in Patients With EGFR+ NSCLC
Oscotec`s SYK inhibitor Program Gets Korea Drug Fund Money
INTERVIEW: Oscotec Lays Out Global Ambitions For RA, Cancer Drugs
G-749, a novel FLT3 Kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia.
"Global Immune Thrombocytopenia (ITP) Market Insights, Epidemiology, and Forecasts, 2017-2028 : Focus on United States, Germany, Spain, Italy, France, and the United Kingdom, and Japan"
AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications